Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up.

Joost H van den BergBianca HeemskerkNienke van RooijRaquel Gomez-EerlandSamira MichelsMaaike van ZonRenate de BoerNoor A M BakkerAnnelies Jorritsma-SmitMarit M van BuurenPia KvistborgHergen SpitsRemko SchotteHenk MalloMatthias KargerJoris A van der HageMichel W J M WoutersLoes M PronkMarnix H Geukes FoppenChristian U BlankJos H BeijnenBastiaan NuijenTon N SchumacherJohn B A G Haanen

Published in: Journal for immunotherapy of cancer (2021)

The clinical results from this study confirm the robustness of TIL therapy in metastatic melanoma and the potential role of neoantigen-specific T cell reactivity. In addition, the data from this study supported the rationale to initiate an ongoing multicenter phase III TIL trial.

Keyphrases

phase iii
clinical trial
open label
double blind
machine learning
mesenchymal stem cells
risk assessment
bone marrow
human health